11.12.24 -- You Still Can't Find Your Providential CDMO?

Cell clumps may be present prior to administration of your final drug product. In the absence of regulatory guidance, we recommend establishing a risk management strategy for control of particulates.

Discover how specialized expertise in plasmid DNA manufacturing can propel your innovative therapies forward and transform patient care.

As the landscape of CAR T-cell therapies evolves, these treatments are becoming more precise in targeting cancer cells and overcoming production challenges, and are poised to revolutionize oncology.

Explore our comprehensive methods for assessing DNA purity and integrity in AAV products to ensure the highest quality gene therapies for your patients.

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

Patient safety is paramount in the promising field of CAR-T therapy. Let's examine a comprehensive monitoring approach using advanced flow cytometry and genomics.

Medical Monitors interact with nearly all functional roles on a study team and more experienced monitors often support and mentor less-experienced colleagues.

Advancements in viral vector design and manufacturing have yielded significant improvements in key areas. Download the E-Book to keep abreast of innovations in this dynamic and rapidly evolving space.

Review the advantages and limitations of transcriptional assays versus reporter gene assays and how the transcriptional assay compares to ddPCR and flow cytometry for analysis of CGTs.

This study compares two important mRNA capping technologies by evaluating the mRNA integrity, percent Cap1 content, dsRNA content, in vivo expression, and innate immune activation in mice.

When it comes to furthering AAV's potential in the wider biopharmaceutical pipeline, partnering with a CDMO that can foment an optimal analytical and manufacturing strategy is crucial.

The streamlined AAV transient transfection platform de-risks your path to IND and reduces complexity and timeline for lengthy process and analytical development.

Uncover how this optimized process for leukapheresis ensures consistency in cell viability and recovery while preserving immune cell populations across multiple donor samples.

Accelerate your path to IND readiness with POSTmark, a fully mirrored platform that streamlines R&D to cGMP scale-up in just 9-12 months while minimizing time, costs, and risks.

With NxGen technology on the NanoAssemblr Blaze, important studies can be conducted efficiently with a process that mirrors a clinical scale implementation.

Our commitment to continuous innovation enhances efficiency and safety, ensuring that patients can access these groundbreaking therapies sooner.

Our gene therapy viral vector process development and manufacturing capabilities are designed to confidently and rapidly progress your products from gene to market through development.

A traditional MES is too complex. Our solution is disrupting the market with a modern, cloud-based alternative that is fast to deploy, simple to configure, easy to use, and cost-effective.

Our robust analytical capabilities support development processes and ensure our products are well characterized, safe and meet regulatory guidelines.